Theragenics, a medical device company serving the surgical products and prostate cancer treatment markets, reported net earnings of $1.19m for the second quarter ended 30 June 2011, compared to $782,000 for the same period in 2010.
The company’s operating income for the second quarter of 2011 was $2m, compared to $1.45m for the same period in 2010.
For the six months ended 30 June 2011, the company reported net earnings of $1.64m, compared to $926,000 for the same period in 2010.
Theragenics’ operating income was $2.89m for the six months of 2011, compared to $2.11m for the same period in 2010.
Theragenics Chairman and CEO Christine Jacobs said their strategy of delivering surgical product growth and maximizing their brachy segment is producing results.